Tvardi Therapeutics, Inc. (TVRD) Stock Ticker
TVRD right now
Market factors today
Unlock the full TVRD picture
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD stock facts
| Ticker symbol | TVRD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $11.9M |
| CEO | Imran Alibhai |
| Employees | 12 |
| Headquarters | Sugar Land, TX, US |
| IPO date | 2014-01-31 |
| Website | tvarditherapeutics.com |
What you can see for TVRD on Tickr
Live TVRD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TVRD report.
Rankings
FAQ
What is the ticker symbol for Tvardi Therapeutics, Inc.?
The ticker symbol for Tvardi Therapeutics, Inc. is TVRD, listed on the NASDAQ.
What is TVRD?
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical…